A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer

PURPOSE: To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colo...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Laheru, Dan, Croghan, Gary, Bukowski, Ronald, Rudek, Michelle, Messersmith, Wells, Erlichman, Charles, Pelley, Robert, Jimeno, Antonio, Donehower, Ross, Boni, Joseph, Abbas, Richat, Martins, Patricia, Zacharchuk, Charles, Hidalgo, Manuel
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2008
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3086427/
https://ncbi.nlm.nih.gov/pubmed/18765554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0433
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk